Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879988 | 0.89 | FLT3 (0.46) | FLT3GSK3BCA1CA2CA5A | |
| SCHEMBL23880020 | 0.86 | CA1 (0.49) | CA1CA2CA5ACA5B | |
| SCHEMBL23880019 | 0.85 | ALDH1A1 (0.48) | CA1CA2CA5ACA5B | |
| SCHEMBL23879983 | 0.85 | CA1 (0.47) | CA1CA2CA5ACA5B | |
| SCHEMBL28319778 | 0.85 | FLT3 (0.67) | FLT3GSK3BCA1CA2CA5A | |
| SCHEMBL20533135 | 0.84 | GRM5 (0.44) | — | |
| SCHEMBL20532909 | 0.84 | KDM1A (0.45) | — | |
| SCHEMBL19869251 | 0.82 | GRM5 (0.43) | — | |
| SCHEMBL23880005 | 0.80 | CA1 (0.44) | CA1CA2CA5ACA5BKCNN4 | |
| SCHEMBL22340587 | 0.80 | BCHE (0.49) | FLT3CA1CA2CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136301-B2 | Broad spectrum antiviral compounds and uses thereof | The Regents of the University of California, A California Corporation et al. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136301-B2 | Broad spectrum antiviral compounds and uses thereof | MAVS, EIF2AK2, ZC3HAV1 | FLT3 1919/4885GSK3B 3145/4885CA1 4846/4885 |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | FLT3 1408/4885GSK3B 2273/4885CA1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.